致力于淋巴细胞恶性疾病的临床诊治和转化研究，以通讯/第一作者在《CANCER CELL》、《NATURE GENETICS》、《BLOOD》、《MOLECULAR CANCER》、《SIGNAL TRANSDUCT TARGET THER》、《J HEMATOL ONCOL》、《LANCET HAEMATOL》、《CLIN CANCER RES》等国际权威杂志发表文章101余篇，总影响因子超过1200分。聚焦鲜明亚洲特点的高发侵袭性淋巴瘤，揭示NK/T细胞淋巴瘤致病机制，率先提出基于分子遗传学、表达谱特征、细胞来源、EB病毒潜伏感染类型及病毒基因表达特征和靶向治疗策略的NKTCL分子分型，首创培门冬酶肌注联合口服地塞米松、依托泊苷的“无输液”方案，使I/II期NKTCL患者的2年总生存率达到91.4%。牵头完成国内第一个抗原嵌合受体的T细胞（CAR-T）的临床研究，使CD19 CAR-T益基利仑赛成为国内首个上市的CAR-T疗法。率先提出巨噬细胞、Treg和髓细胞来源等免疫抑制细胞是诱发CAR-T耐药的关键因素。以生物学行为这一独特角度，针对淋巴瘤细胞病理生理改变，阐明化疗耐药的预警分子和化疗增敏的关键靶点，为设计靶向干预新途径奠定理论基础。 科技奖项： 相关成果以第一完成人获2018年国家科技进步二等奖，2017年教育部自然科学一等奖、2017年教育部科技进步一等奖、2012年华夏医学科技奖一等奖和2017年上海市自然科学牡丹奖等。主持国家863 重大项目、国家自然科学基金和省部级重点项目多项。 发明专利： 1、赵维莅；孙芮；郑重；miRNA抑制剂在制备治疗和/或预防淋巴瘤的药物中的应用，2022-09-16，中国，ZL 2020 1 1140272.3 2、赵维莅；熊杰；EB病毒BALF4蛋白的抗原表位，2022-08-16，中国，ZL 2020 1 0205008.7 3、赵维莅；熊杰；EB病毒BALF3蛋白的抗原表位，2022-08-16，中国，ZL 2020 1 0205009.1 4、赵维莅；许彭鹏；付迪；王黎；俞浩；刘以哲；熊慧；一种用于淋巴瘤预后判断的方法、试剂盒及应用，2022-05-20，中国，ZL 2020 1 0090278.8 5、赵维莅；王黎；赵萍；房莹；一种siRNA分子及其应用，2022-05-13，中国，ZL 2019 1 0349684.9 6、赵维莅；熊杰；孙晓建；程澍；一种斑马鱼NK/TCL肿瘤模型的构建方法及其应用，2022-05-06，ZL201810553147.1 7、赵维莅; 王黎; 郑重; 薛雯; 张翼飞; 宁光；黄连素在制备治疗B细胞淋巴瘤的药物中的应用，2018-04-17，中国，ZL 2015 1 0167823.8 8、王黎; 赵维莅; 熊杰; 郑重; 纪濛濛；黄连素在制备治疗T细胞淋巴瘤的药物中的应用，2018-04-10，中国，ZL 2015 1 0083058.1 9、朱伟嵘; 赵维莅; 沈小珩; 王黎；一种治疗B细胞淋巴瘤的苓黄合剂及其应用，2018-08-21，中国，ZL 2015 1 0364639.2 10、赵维莅; 施文瑜; 肖丹; 王黎；二甲双胍在制备治疗淋巴瘤疾病药物中的应用，2014-01-29，中国，ZL 2011 1 0282718.0 11、赵维莅; 陈赛娟; 张群岭; 杨帆 一组能有效下调PRDM1β表达的siRNA分子及其应用，2012-12-05，中国，ZL 2010 1 0127886.8   12、陈赛娟；陈竺；王兰；赵维莅；孙汉董；毛萼乙素在制药中的应用，2008-02-27，中国，ZL 2005 1 0110089.8   13、陈竺；陈赛娟；赵维莅；王兰；刘元华；阎金松；一种治疗B细胞淋巴瘤的药物组合物 ，2007-11-07，中国，ZL 2005 1 0112147.0   著作： 1、淋巴瘤的中西医结合治疗，科学出版社，2021年，主编 2、中国淋巴瘤标准数据集（2021版），中国协和医科大学，2021年，主编 3、癌症转化医学研究中的靶向治疗，上海科学技术出版社，2017年，主编 4、威廉姆斯血液学 第九版（翻译版），人民卫生出版社，2018年，副主译 重要论文： 1. Lu H, Xu X, Fu D, Gu Y, Fan R, Yi H, He X, Wang C, Ouyang B, Zhao P, Wang L, Xu P, Cheng S, Wang Z, Zou D, Han L, Zhao W. Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis. Cell Host Microbe. 2022 Aug 10;30(8):1139-1150.e7. doi: 10.1016/j.chom.2022.07.003. 2. Sun R, Zhang PP, Weng XQ, Gao XD, Huang CX, Li W, Hu XX, Xu PP, Cheng L, Jiang L, Fu D, Qu B, Zhao Y, Feng Y, Dou HJ, Zheng Z, Zhao WL. Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells. Signal Transduct Target Ther. 2022 Mar 18;7(1):80. doi: 10.1038/s41392-022-00895-2. 3. Xu PP, Huo YJ, Zhao WL. All roads lead to targeted diffuse large B-cell lymphoma approaches. Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013. 4. Wang N, Qin W, Zheng Z, Zhao M, Xiong J, Fang H, Sun R, Wang Y, Li C, Dong L, Sun X, Wang L, Xu P, Cheng S, Xu H, Zhang F, Zhao W. Hepatitis B virus-associated follicular lymphoma presents T-cell inflamed phenotype and response to lenalidomide. Cancer Commun (Lond). 2022 Feb;42(2):170-174. doi: 10.1002/cac2.12241. Epub 2021 Dec 1. 5. Zhao CX, Yan ZX, Wen JJ, Fu D, Xu PP, Wang L, Cheng S, Hu JD, Zhao WL. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis. Mol Cancer. 2021 Dec 1;20(1):153. doi: 10.1186/s12943-021-01458-9. 6. Xiong J, Wang N, Zhong HJ, Cui BW, Cheng S, Sun R, Chen JY, Xu PP, Cai G, Wang L, Sun XJ, Huang JY, Zhao WL. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential. EBioMedicine. 2021 Oct;72:103614. doi: 10.1016/j.ebiom.2021.103614. Epub 2021 Oct 7. 7. Qin W, Jiang X, You J, Guo R, Shi Q, Dong L, Shen R, Cheng S, Xu P, Qian Y, Li B, Wang L, Zhao W. Deauville score evaluation of interim PET/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3347-3350. doi: 10.1007/s00259-021-05310-6. Epub 2021 Mar 23. 8. Wang S, Wang L, Hu J, Qian W, Zhang X, Hu Y, Zhu Q, Chen B, Wu D, Chang CH, Xu P, Zheng X, Wei J, Liu Y, Cui G, Tang Y, Ma Y, Huang H, Yi H, Zhao W.Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.Cancer Commun (Lond). 2021 Mar;41(3):229-239. doi: 10.1002/cac2.12126. Online ahead of print. 9. Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, Ji MM, Zhao WL.CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021 Jan 11;6(1):10. doi: 10.1038/s41392-020-00437-8. 10. Wang L, Qin W, Huo YJ, Li X, Shi Q ,Rasko JEJ, Janin A , Zhao WL. Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther. 2020Mar 6 ,5(1)15,doi:10.1038/ s41392-020-0113-2.   11. Cai MC, Cheng S, Wang X, Hu JD, Song YP, Huang YH, Yan ZX, Jiang YJ, Fang XS, Zheng XY, Dong LH, Ji MM, Wang L, Xu PP, Zhao WL. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. Genome Med. 2020 Apr 30;12(1):41. doi: 10.1186/s13073-020-00739-0. PMID: 32349779; PMCID: PMC7191773. 12. Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, Zhong HJ, Cheng S, Ou-Yang BS, Hu Y, Zhang X, Xu B, Qian WB, Tao R, Yan F, Hu JD, Hou M, Ma XJ, Wang X, Liu YH, Zhu ZM, Huang XB, Liu L, Wu CY, Huang L, Shen YF, Huang RB, Xu JY, Wang C, Wu DP, Yu L, Li JF, Xu PP, Wang L, Huang JY, Chen SJ, Zhao WL. Genomic and transcriptomic characterization of natural-killer T-cell lymphoma. Cancer Cell.2020 Mar 16;37(3):403. doi: 10.1016/j.ccell.2020.02.005. 13. Yan ZX, Li L, Wang W, OuYang BS, Cheng S, Wang L, Wu W, Xu PP, Muftuoglu M, Hao M, Yang S, Zhang MC, Zheng Z, Li J, Zhao WL. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. Clin Cancer Res. 2019 Dec 1;25(23):6995-7003. doi: 10.1158/1078-0432.CCR-19-0101. Epub 2019 Aug 23. 14. Zhong HJ, Chen J, Cheng S, Chen S, Shen R, Shi Q, Xu P, Huang H, Zhang M, Wang L, Wu D, Zhao W. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma. EBioMedicine. 2019 Mar;41:167-174. doi: 10.1016/j.ebiom.2019.02.048. Epub 2019 Mar 1. 15. Xu PP, Fu D, Li JY, Hu JD, Wang X, Zhou JF, Yu H, Zhao X, Huang YH, Jiang L, Liu F, Su LP, Chen ZW, Zeng QS, Chen JP, Fang MY, Ma J, Liu T, Song YP, Yu K, Li Y, Qiu LG, Chen XQ, Gu J, Yan JS, Hou M, Huang HY, Wang L, Cheng S, Shen Y, Xiong H, Chen SJ, Zhao WL. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. Lancet Haematol. 2019 Jun;6(6):e328-e337. doi: 10.1016/S2352-3026(19)30051-1. 16. Zheng Z, Sun R, Zhao HJ, Fu D, Zhong HJ, Weng XQ, Qu B, Zhao Y, Wang L, Zhao WL. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Mol Cancer. 2019 Mar 30;18(1):54. doi: 10.1186/s12943-019-0977-3. 17. Xiong J, Zhao WL. Advances in multiple omics of natural-killer/T cell lymphoma.J Hematol Oncol. 2018 Dec 4;11(1):134. doi: 10.1186/s13045-018-0678-1. 18. Xu PP, Sun C, Cao X, Zhao X, Dai HJ, Lu S, Guo JJ, Fu SJ, Liu YX, Li SC, Chen M, McCord R, Venstrom J, Szafer-Glusman E, Punnoose E, Kiermaier A, Cheng G, Zhao WL.Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies.EBioMedicine. 2018 Jul;33:94-104. doi: 10.1016/j.ebiom.2018.06.010. Epub 2018 Jun 20. 19. Xiong J, Zhao WL. Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma. EBioMedicine. 2018 Feb;28:5-6. doi: 10.1016/j.ebiom.2018.01.036. Epub 2018 Jan 31. 20. Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, Liu F, Leboeuf C, Wang L, Ye J, Lu YM, Janin A, Cheng S, Zhao WL.Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.Haematologica. 2018 Apr;103(4):679-687. doi: 10.3324/haematol.2017.182444. Epub 2018 Jan 5. 21. Xu PP, Xiong J, Cheng S, Zhao X, Wang CF, Cai G, Zhong HJ, Huang HY, Chen JY, Zhao WL.A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.EBioMedicine. 2017 Nov;25:41-49. doi: 10.1016/j.ebiom.2017.10.011. Epub 2017 Oct 12. 22. Zheng Z, Xu PP, Wang L, Zhao HJ, Weng XQ, Zhong HJ, Qu B, Xiong J, Zhao Y, Wang XF, Janin A, Zhao WL.MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells.J Exp Clin Cancer Res. 2017 Jun 21;36(1):82. doi: 10.1186/s13046-017-0551-z. 23. Xu PP, Zhong HJ, Huang YH, Gao XD, Zhao X, Shen Y, Cheng S, Huang JY, Chen SJ, Wang L, Zhao WL.B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.EBioMedicine. 2017 Feb;16:106-114. doi: 10.1016/j.ebiom.2017.01.027. Epub 2017 Jan 21. 24. Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, Xu PP, Shen Y, Liu H, Janin A, Cheng S, Zhao WL.Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.Autophagy. 2015;11(12):2160-71. doi: 10.1080/15548627.2015.1082024. 25. Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, Huang JY, Wang L, Shen Y, Meng G, Zhou JF, Hu JD, Wang JF, Liu YH, Yang LH, Zhang F, Wang JM, Wang Z, Peng ZG, Chen FY, Sun ZM, Ding H, Shi JM, Hou J, Yan JS, Shi JY, Xu L, Li Y, Lu J, Zheng Z, Xue W, Zhao WL, Chen Z, Chen SJ.Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.Nat Genet. 2015 Sep;47(9):1061-6. doi: 10.1038/ng.3358. Epub 2015 Jul 20. 26. Zheng Z, Cheng S, Wu W, Wang L, Zhao Y, Shen Y, Janin A, Zhao WL.c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.J Hematol Oncol. 2014 Dec 5;7:88. doi: 10.1186/s13045-014-0088-y. 27. Zhang L, Chen QS, Xu PP, Qian Y, Wang AH, Xiao D, Zhao Y, Sheng Y, Wen XQ, Zhao WL.Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation.J Hematol Oncol. 2014 Oct 1;7:75. doi: 10.1186/s13045-014-0075-3. 28. Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y, Romero M, Leboeuf C, Janin A, Chen SJ, Wang L, Zhao WL.MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.Leukemia. 2014 Apr;28(4):880-7. doi: 10.1038/leu.2013.291. Epub 2013 Oct 9. 29. Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, Chen SJ, Zhao WL.Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.J Hematol Oncol. 2013 Jul 18;6:53. doi: 10.1186/1756-8722-6-53. 30. Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A, Zhao WL.Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.Haematologica. 2011 Jun;96(6):927-31. doi: 10.3324/haematol.2010.037689. Epub 2011 Feb 17. 31. Wang L, Shi WY, Wu ZY, Varna M, Wang AH, Zhou L, Chen L, Shen ZX, Lu H, Zhao WL, Janin A.Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.J Hematol Oncol. 2010 Sep 9;3:30. doi: 10.1186/1756-8722-3-30. 32. Zhao WL.Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways.Leukemia. 2010 Jan;24(1):13-21. doi: 10.1038/leu.2009.223. Epub 2009 Oct 29. Review. 33. Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B, Shi JY, Wang YY, Wang JH, Chen Y, Li JM, Gu LJ, Tang JY, Shen ZX, Gu BW, Zhao WL, Chen Z, Chen SJ.AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.Leukemia. 2009 Sep;23(9):1598-604. doi: 10.1038/leu.2009.104. Epub 2009 May 21. 34. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL.The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.Leukemia. 2009 Aug;23(8):1507-14. doi: 10.1038/leu.2009.41. Epub 2009 Mar 12. 35. Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW, Ma J, Garcia JF, Song YP, Li JM, Shen ZX, Chen Z, Janin A, Chen SJ.PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.Blood. 2008 Apr 1;111(7):3867-71. doi: 10.1182/blood-2007-08-108654. Epub 2008 Jan 30. 36. Fu JF, Shi JY, Zhao WL, Li G, Pan Q, Li JM, Hu J, Shen ZX, Jin J, Chen FY, Chen SJ. MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders. Leukemia. 2008 Mar;22(3):660-3. doi: 10.1038/sj.leu.2404931. Epub 2007 Aug 30. 37. Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y, Garcia JF, Shen ZX, Chen Z, Janin A, Chen SJ, Zhao WL.Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.Blood. 2007 Jul 1;110(1):339-44. Epub 2007 Mar 22. 38. Wang L, Zhao WL, Yan JS, Liu P, Sun HP, Zhou GB, Weng ZY, Wu WL, Weng XQ, Sun XJ, Chen Z, Sun HD, Chen SJ.Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.Cell Death Differ. 2007 Feb;14(2):306-17. Epub 2006 Jun 16. 39. Zhu YM, Zhao WL, Fu JF, Shi JY, Pan Q, Hu J, Gao XD, Chen B, Li JM, Xiong SM, Gu LJ, Tang JY, Liang H, Jiang H, Xue YQ, Shen ZX, Chen Z, Chen SJ. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res. 2006 May 15;12(10):3043-9. Erratum in: Clin Cancer Res. 2009 Feb 15;15(4):1506 40. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, Cui J, Chen ZM, Cao Q, Yang G, Yao Y, Xia HL, Tong JH, Li JM, Chen J, Xiong SM, Shen ZX, Waxman S, Chen Z, Chen SJ. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005 May;19(5):767-75. doi: 10.1038/sj.leu.2403688. PMID: 15759035. 41. Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med. 2005 Jan;2(1):e12. doi: 10.1371/journal.pmed.0020012. 42. Zhao WL, Daneshpouy ME, Mounier N, Brière J, Leboeuf C, Plassa LF, Turpin E, Cayuela JM, Ameisen JC, Gisselbrecht C, Janin A.Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma.Blood. 2004 Jan 15;103(2):695-7. Epub 2003 Sep 11. 43. Xu L, Zhao WL, Xiong SM, Su XY, Zhao M, Wang C, Gao YR, Niu C, Cao Q, Gu BW, Zhu YM, Gu J, Hu J, Yan H, Shen ZX, Chen Z, Chen SJ.Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia.Leukemia. 2001 Sep;15(9):1359-68. 44. Zhao WeiLi, Wang HL, Wang XF, Wu F, Guo W, Qu B, Shen Z, Wang ZEffects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thromb Res. 2001, 102(3): 197-204.